Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients

November 19, 2019

PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer patients   IRVINE, CALIF. – 19 November 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that five abstracts featuring data…

Read more

Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)

September 28, 2019

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at the European Society for Medical Oncology (ESMO) Congress 2019, taking place from September 27 to October 1 in Barcelona, Spain.…

Read more

Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology

June 20, 2019

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology in the Journal of Molecular Diagnostics. The publication summarized the analytical and clinical validation studies…

Read more

BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes

June 3, 2019

PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 1 June 2019 – Agendia, Inc., a world leader in precision oncology, today announced the presentation of study results…

Read more